Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17440258 | 1.00 | BTK (0.50) | BTKKDM1AMAOBCTSKCA1 | |
| SCHEMBL6418270 | 0.76 | BTK (0.51) | BTKKDM1AMAOBCTSKCA1 | |
| SCHEMBL18929028 | 0.74 | BTK (0.51) | BTKKDM1AMAOBCTSKCA1 | |
| SCHEMBL14100893 | 0.73 | BTK (0.49) | BTKKDM1AMAOBCTSKCA1 | |
| SCHEMBL18901529 | 0.73 | BTK (0.49) | BTKKDM1AMAOBCTSKCA1 | |
| SCHEMBL572248 | 0.73 | BTK (0.51) | BTKKDM1AMAOBCTSKCA1 | |
| SCHEMBL12508237 | 0.72 | BTK (0.50) | BTKKDM1AMAOBCTSKCA1 | |
| SCHEMBL2195440 | 0.72 | BTK (0.50) | BTKKDM1AMAOBCTSKCA1 | |
| SCHEMBL1033706 | 0.72 | BTK (0.50) | BTKKDM1AMAOBCTSKCA1 | |
| SCHEMBL1137056 | 0.72 | BTK (0.50) | BTKKDM1AMAOBCTSKCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9908895-B2 | Tricyclic fused thiophene derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2018-03-06 | — | — | US | disclosed |
| US-20160024109-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | INCYTE HOLDINGS CORPORATION | 2016-01-28 | — | — | US | disclosed |
| US-20160015695-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015695-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | BTK 11/4885KDM1A 1997/4885MAOB 4484/4885 |
| US-20160024109-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | BTK 11/4885KDM1A 1997/4885MAOB 4484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.